“Looking forward to the Coronavirus PR next week
Post# of 145754
![Avatar](/images/ProfileImages/573000060_60093_FD245EF6-37BD-4C88-9356-29519D0376AD.jpeg)
I’m interested in everyone’s thoughts on how the market might respond to the CYDY PR on the phase 2 IND for treatment of the corona virus with leronlimab. Obviously, a treatment now is much more important than a vaccine because it MAY save lives now and not in 18 months.
My biggest concern: that the stinky, stinky OTC label may hold us back from skyrocketing like these other biotechs have. I don’t have the time to do the research, but are any of the other corona virus biotechs, that had an SP increase, on the OTC? If so, how much did the SP increase?
Logic would tell you that a company with a potential treatment would have more value right now than a vaccine, but this is CYDY and the OTC so logic doesn’t apply.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)